---
title: Webinars
---

# ASA-BI Webinars

* "[Bayesian designs in oncology clinical trials](#webinar1)",
  Dr. Lili Zhao (July 25, 2017)
* "[How the ICH E9 addendum around estimands may impact our clinical
  trials](#webinar2)", Dr. Frank Bretz (August 17, 2017)
* "[Impact of model complexity on operating characteristics of
  adaptive dose-finding methods](#webinar3)", Dr. Alexia Iasonos
  (September 11th, 2017)
* "[Phase I trials design with dose expansion cohort](#webinar4)",
  Dr. Jincheng Shen (October 17th, 2017)
* "[Blinded ongoing aggregate safety evaluation
  (Blinded-OASE)](#webinar5)", Dr. Greg Ball and Dr. William Wang
  (November 8th, 2017)
* "[Assessing covariate effects using Jeffrey’s-type prior in the Cox
  model in the presence of a monotone partial likelihood](#webinar6)",
  Dr. Jing Wu (December 6th, 2017)
* "[Dose-escalation trials without monotonicity assumption: A weighted
  differential entropy approach](#webinar7)", Dr. Thomas Jaki
  (February 27th, 2018)
* "[EMPA-REG Outcome® - A Cardiovascular Outcome Trial designed
  according to the FDA Guidance 'Diabetes Mellitus– Evaluating
  Cardiovascular Risk in New Anti-diabetic Therapies to Treat Type 2
  Diabetes'](#webinar8)", Dr. Stefan Hantel (April 5th, 2018)
* "[A practical design for a dual-agent dose-escalation trial that
  incorporates pharmacokinetic data](#webinar9)", Dr. Amy Cotterill
  (April 24th, 2018)

## ASA-BI Statistics Webinar Series # 1 { #webinar1 }

* *Topic:* Bayesian designs in oncology clinical trials
* *Speaker:* Dr. Lili Zhao, Research Assistant Professor, Biostatistics Department, University of Michigan, USA
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---1---Lili-Zhao.pdf)
* *Date:* July 25th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
* [Slides](media/webinars-asa-bi/presentation-webinar1-Lili-Zhao.pdf)

## ASA-BI Statistics Webinar Series # 2 { #webinar2 }
* *Topic:* How the ICH E9 addendum around estimands may impact our clinical trials
* *Speaker:* Dr. Frank Bretz, Global Head, Statistical Methodology and Consulting Group, Novartis, Switzerland 
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---2---Frank-Bretz.pdf)
* *Date:* August 17th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
* [Slides](media/webinars-asa-bi/presentation-webinar2-Frank-Bretz.pdf)

## ASA-BI Statistics Webinar Series # 3 { #webinar3 }
* *Topic:* Impact of model complexity on operating characteristics of adaptive dose-finding methods
* Speakers: Dr. Alexia Iasonos, Associate Attending Biostatistician, Memorial Sloan Kettering Cancer Center and Dr. Nolan Wages, Associate Professor, University of Virginia, USA
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---3---Alexia-Iasonos---Nolan-Wages.pdf)
* *Date:* September 11th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
* [Slides](media/webinars-asa-bi/presentation-webinar3-Alxia-Iasonos-and-Nolan-Wages.pdf)

## ASA-BI Statistics Webinar Series # 4 { #webinar4 }
* *Topic:* Phase I trials design with dose expansion cohort
* *Speaker:* Dr. Jincheng Shen, Assistant Professor, Department of Population Health Sciences, University of Utah, USA
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---4---Jincheng-Shen.pdf)
* *Date:* October 17th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
* *Slides:* Upon request

## ASA-BI Statistics Webinar Series # 5 { #webinar5 }
* *Topic:* Blinded ongoing aggregate safety evaluation (Blinded-OASE) 
* *Speaker:* Dr. Greg Ball, Principal Statistician and Dr. William (Bill) Wang, Executive Director, Merck Pharmaceuticals, Inc.  
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---5---Greg-Ball---William-Wang.pdf)
* *Date:* November 8th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
* [Slides](media/webinars-asa-bi/presentation-webinar5-Greg-Ball-and-William-Wang.pdf)

## ASA-BI Statistics Webinar Series # 6 { #webinar6 }
* *Topic:* Assessing covariate effects using Jeffrey’s-type prior in the Cox model in the presence of a monotone partial likelihood
* *Speaker:* Dr. Jing Wu, Assistant Professor, University of Rhode Island, USA
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---6---Jing-Wu.pdf)
* *Date:* December 6th, 2017
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
*  [Slides](media/webinars-asa-bi/presentation-webinar6-Jing-Wu.pdf)

## ASA-BI Statistics Webinar Series # 7 { #webinar7 }
* *Topic:* Dose-escalation trials without monotonicity assumption: A weighted differential entropy approach
* *Speaker:* Dr. Thomas Jaki, Professor of Statistics, Lancaster
  University, UK
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---7---Thomas-Jaki.pdf)
* *Date:* February 27th, 2018
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
*  [Slides](media/webinars-asa-bi/presentation-webinar7-Thomas-Jaki.pdf)

## ASA-BI Statistics Webinar Series # 8 { #webinar8 }
* *Topic:* EMPA-REG Outcome® - A Cardiovascular Outcome Trial designed according to the FDA Guidance "Diabetes Mellitus– Evaluating Cardiovascular Risk in New Anti-diabetic Therapies to Treat Type 2 Diabetes"
* *Speaker:* Dr. Stefan Hantel, Therapeutic Area Statistician, Boehringer Ingelheim, Germany
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---8---Stefan-Hantel.pdf)
* *Date:* April 5th, 2018
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A

## ASA-BI Statistics Webinar Series # 9 { #webinar9 }
* *Topic:* A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data
* *Speaker:* Dr. Amy Cotterill, Senior Statistician, Cancer Research UK Clinical Trials Unit, University of Birmingham, UK
* [Abstract](media/webinars-asa-bi/Webinar-series-flyer---9---AmyCotterill.pdf)
* *Date:* April 24th, 2018
* *Time:* 9:00-10:00 EST (New York), including 10-minute Q&A
